Announcement on Signing License Agreement for CD20*CD3 Bispecific Antibody (ICP-B02/CM355) between Subsidiary and Prolium

About this update from Innocare Pharma Ltd. Class A

Announcement on Signing License Agreement for CD20*CD3 Bispecific Antibody (ICP-B02/CM355) between Subsidiary and Prolium The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Innocare Pharma Ltd. Class A